Addiction Treatment Billing Software

Medical Billing Software for Addiction Treatment Billing Companies

Short answer

Addiction treatment billing is structurally unlike most behavioral health billing. Revenue depends on correctly matching ASAM levels of care to payer-specific per-diem H-codes, managing prior authorization and concurrent utilization review at every level from intensive outpatient through residential and detox, and keeping urine drug testing documentation tight enough to survive OIG and payer audit scrutiny. Medication-assisted treatment billing adds its own code family, and MHPAEA parity requirements impose limits on how commercial insurers can treat SUD services relative to medical benefits. A billing company managing substance use disorder treatment facilities needs software that surfaces denial reasons at the service-line level, tracks authorization and concurrent-review status per claim, and gives billers a clear A/R queue across multiple client facilities. Medi does that work across a mixed book of practices without replacing clinical coders or submitting authorization requests. See CMS MHPAEA information and SAMHSA treatment guidance.

Why SUD billing is different

Three things separate addiction treatment billing from general behavioral health work, and together they make this one of the more administratively demanding revenue cycles in the specialty.

The first is ASAM level of care. The American Society of Addiction Medicine's patient placement criteria define a continuum from early intervention through medically managed inpatient detox. Each level maps to a different code family, a different payer authorization process, and a different per-diem or per-unit rate structure. When a patient steps up from intensive outpatient to residential, the billing switches from hourly or session CPT codes to a per-diem H-code. When the clinical team steps a patient down from residential to PHP, the authorization must change before billing changes, or the claim denies. Tracking those transitions across a multi-facility book requires clear per-claim status visibility.

The second is authorization and concurrent review. Residential and inpatient levels almost universally require prospective authorization, and most commercial payers conduct concurrent or continued-stay reviews every three to seven days while the patient is at a higher level. Those reviews can authorize continued stay, step the patient down, or deny further days retroactively. For billing companies, the practical problem is knowing which claims are covered by a current authorization versus which are pending a concurrent review that has not yet returned.

The third is urine drug testing. UDT is clinically appropriate in addiction treatment across levels of care, but it is also one of the highest-scrutiny billing areas in behavioral health. The OIG has produced enforcement actions and audit findings against facilities and labs billing UDT at patterns that suggest it was a standing order rather than an individualized clinical decision.

ASAM levels of care and how they map to billing

The ASAM criteria use a decimal numbering system. Not every payer accepts every level, and Medicaid coverage for each level varies significantly by state.

H-code definitions are established by HCPCS and may be modified at the state Medicaid level. Commercial payers may not recognize all H-codes; some require CPT codes even for residential services. Confirm accepted codes with each payer before billing a new level.

Sources: ASAM criteria overview, Behave Health H-code reference, Behave Health residential codes H0017-H0019.

Per-diem H-codes versus CPT therapy codes

Two code frameworks coexist in SUD billing, and many facilities use both within the same patient episode.

H-codes are HCPCS Level II codes, typically billed per diem, that bundle the facility's clinical programming for a level of care into a single daily rate. H0015 covers IOP services; H0017 covers general residential behavioral health programming; H0018 covers short-term residential treatment under 30 days; H0019 covers long-term residential treatment of 30 days or more. Room and board are always excluded from H-code per diems and are typically not reimbursable by commercial insurance. H-codes are the billing backbone for Medicaid-funded SUD treatment and are accepted by many commercial payers, though acceptance varies.

CPT therapy codes are used for individually billable professional services, often at the outpatient and IOP levels where a therapist or physician delivers a discrete session. The evaluation and management code at intake is typically 90791 (psychiatric diagnostic evaluation without medical services) or 90792 (with medical services). Individual psychotherapy is billed by time: 90832 for sessions of 16 to 37 minutes, 90834 for 38 to 52 minutes, 90837 for 53 minutes or longer. Group psychotherapy is 90853, billed once per patient per group session, not once per group. The 90853 rule catches many facilities off guard: eight patients in a group generate eight 90853 claims, each submitted under the appropriate rendering clinician.

The tension between frameworks is a real billing problem. A patient at ASAM Level 2.1 who receives a structured IOP program may have their daily program bundled under H0015 while also receiving an individual therapy session from a separately credentialed clinician who bills 90837. Whether the payer allows both on the same date, or considers the individual session bundled into the H0015 rate, depends on the payer's bundling policy and must be verified before billing.

Sources: Behave Health H0015 overview, CMS billing and coding for psychiatry services (A57480).

Medication-assisted treatment billing

Medication-assisted treatment uses FDA-approved medications alongside counseling to treat opioid use disorder and alcohol use disorder. The billing structure depends entirely on the treatment setting.

For opioid treatment programs (OTPs) certified under 42 CFR Part 8 and enrolled with CMS, Medicare billing uses G-code bundles. G2067 covers a weekly methadone bundle that includes dispensing, counseling, group therapy, and toxicology when performed. G2068 through G2072 cover weekly buprenorphine bundles differentiated by formulation: oral, injectable, implant insertion, implant removal, and combined insertion-removal. G2073 covers weekly naltrexone. These are weekly bundled codes; billing more than one unit per patient per seven-day period is not permitted.

For office-based opioid treatment (OBOT) outside a certified OTP, the billing model is different. A qualifying physician prescribing buprenorphine bills E/M codes for the visit, the pharmacy fills the prescription, and the clinic does not separately bill a G-code bundle. The OTP bundled G-codes apply only to Medicare-enrolled OTPs; using them for non-OTP office practices is a billing error.

Medicaid MAT billing varies by state. H0020 covers methadone administration and associated services at licensed programs in many state Medicaid systems. State Medicaid programs may have distinct codes, rate structures, or carve-out arrangements for MAT, so billing companies need to verify the specific code set and authorization requirements for each state where a client facility operates.

Sources: CMS OTP billing and payment, CMS Chapter 39, Opioid Treatment Programs, SAMHSA MAT information.

Urine drug testing and OIG audit scrutiny

Urine drug testing in addiction treatment faces the same enforcement landscape as in pain management, with some differences in clinical context. Testing is clinically standard at most levels of care to confirm treatment adherence, identify relapse, and guide medication decisions. That clinical legitimacy does not shield high-frequency, high-panel testing from audit.

Presumptive drug testing is reported with CPT 80305 (optical observation only), 80306 (instrument-assisted optical), or 80307 (instrument chemistry). Definitive drug testing, which identifies specific drugs and quantities with greater sensitivity, uses HCPCS G0480 through G0483 for Medicare, tiered by the number of drug classes tested. Most payers reimburse one presumptive and one definitive test per date of service; billing both a presumptive and definitive panel at the same visit requires documented clinical justification for that patient on that date. Specimen validity testing is generally not separately billable, because it is considered included in the presumptive test codes.

The OIG has made UDT a recurring enforcement focus. A 2016 OIG report found that Medicare improperly paid $66 million for specimen validity tests billed alongside UDT codes that already included specimen validity. The pattern that draws attention is facility-wide standing orders for the highest-panel definitive code at every visit, for every patient, regardless of clinical context. For addiction treatment, the frequency question is particularly sharp: multiple UDTs per week in an IOP setting without documentation tying each test to an individual clinical decision has produced federal investigations and settlement agreements.

The billing company's role is not to make the clinical decision. It is to confirm that documentation exists to support the billing pattern and to flag facilities where testing frequency is high relative to level of care.

Sources: OIG combating the opioid epidemic, CMS billing and coding for urine drug testing (A55030), OIG enforcement actions.

Prior authorization and concurrent utilization review

Prior authorization in SUD treatment is not a one-time pre-check. It is a running process that follows the patient through every level-of-care transition.

Outpatient services at ASAM Level 1 may require authorization for the initial episode, then periodic re-authorization. IOP at Level 2.1 commonly requires initial authorization for a defined number of days or weeks, then concurrent review every two weeks. PHP at Level 2.5 and higher-intensity residential levels typically require authorization before admission and concurrent review every three to seven days. Inpatient detox at Levels 3.7 and 4 may require review every one to three days.

The clinical documentation expected at concurrent review is specific: substance use history, primary diagnosis and co-occurring conditions, ASAM placement justification, measurable treatment goals, progress against those goals, and the rationale for continued stay at the current level rather than a step-down. When that documentation is absent, vague, or not provided to the reviewer before the deadline, the continued-stay authorization is denied, and the clinical team may not know until the claim comes back unpaid.

For billing companies, the workflow problem is visibility. A billing company managing ten SUD facilities may have ten different payer portals, ten different documentation submission timelines, and ten different authorization expiration windows active at once. Without a single surface showing auth status per claim, billers spend time reconstructing the auth history from payer calls and EHR notes before they can work the claim.

Single-case agreements are a related complexity in this space. SUD treatment facilities with out-of-network relationships negotiate SCAs with commercial payers for individual patient episodes when no in-network facility can meet the patient's needs. SCAs establish a per-diem rate, the authorized level of care, the initial stay length, and the concurrent review schedule. Billing under an SCA requires the authorization number on every claim, and the SCA's concurrent review schedule can be tighter than standard in-network timelines.

Sources: DOL MHPAEA new rules for providers, NY OASAS utilization review guidance.

Parity rules under MHPAEA

The Mental Health Parity and Addiction Equity Act of 2008 prohibits group health plans from imposing more restrictive financial requirements or treatment limitations on SUD benefits than on comparable medical or surgical benefits. In September 2024, the Departments of Labor, HHS, and Treasury issued final rules that significantly strengthen parity requirements, including new obligations for plans to evaluate and document that their nonquantitative treatment limitations (NQTLs) for SUD services are no more restrictive than those for medical services.

NQTLs include prior authorization requirements, concurrent review frequency, out-of-network reimbursement rates, and network composition standards. The 2024 rules require plans to demonstrate through comparative analyses that these restrictions, when applied to SUD benefits, do not exceed what is applied to medical benefits. Plans that cannot produce that analysis on request are out of compliance.

For billing companies, parity matters in two ways. First, when a commercial payer applies more frequent concurrent review to a residential SUD claim than to a comparable medical admission, that disparity may be a MHPAEA violation. Billing companies are not enforcement bodies, but identifying consistent patterns in how a payer handles SUD concurrent review can support appeals. Second, parity applies to in-network adequacy. Many SUD treatment facilities operate out-of-network because commercial plans have thin SUD provider networks. SCA negotiation and appeal language increasingly references parity network-adequacy requirements.

Sources: CMS MHPAEA page, DOL MHPAEA final rule fact sheet, Federal Register MHPAEA 2024 final rule.

Where SUD billing companies lose money

The denial patterns that erode revenue in addiction treatment billing cluster around a handful of causes, most of which are recoverable with the right workflow infrastructure.

Concurrent-review gaps are the most common source of days that do not pay. The documentation is not delivered to the payer before the review deadline, the continued-stay authorization is denied, and the facility is left holding claims for days that were clinically appropriate but administratively uncovered. These denials are often grievable, but the appeal process is time-consuming and not always successful. The fix is tracking review deadlines per patient, per payer, per authorization, before the deadline passes.

Level-of-care mismatch denials happen when the billed level does not match the clinical documentation's ASAM justification, or when a patient steps to a new level and claims are submitted under the old code before the authorization is updated. A facility billing H0017 residential when the patient's documentation only supports ASAM Level 2.5 PHP will see recoupment, not just initial denial.

UDT-pattern denials accumulate when payers' internal edits flag high-frequency definitive testing without individual-visit justification. These sometimes manifest as retrospective audits rather than claim-by-claim denials, which is why they do not always surface in the denial queue until a significant balance is at risk.

Authorization-expiration denials are common at the residential-to-step-down transition. When a patient remains in residential care past the authorized days while a step-down is being arranged, those final days lack coverage unless a concurrent review was requested and granted. The billing window to catch these is short.

CPT-bundling issues at IOP arise when H0015 per-diem claims are submitted on the same date as individual CPT therapy codes that the payer considers included in the IOP rate. Knowing which payers allow unbundling and which do not requires a maintained payer matrix.

How Medi handles addiction treatment billing-company workflows

Medi is a billing-company-first RCM operating layer. It does not auto-code, it does not replace billers, and it does not submit prior authorization requests or concurrent review documentation to payers. It organizes the work billers already do, across multiple facilities, in one place.

For authorization and concurrent review status, Medi surfaces auth tracking at the claim level. Billers working a residential facility can see which claims carry an active authorization number, which are pending a continued-stay review, and which moved to a denial queue because the concurrent review was denied. The billing company is still responsible for submitting review documentation through payer portals or the facility EHR, but Medi gives the team one surface showing where each claim stands rather than a separate login per facility.

For denial management, Medi translates CARC and RARC codes into plain language at the individual service line. A denial with CARC 96 on an H0018 residential claim calls for a different action than a CARC 50 on an H0015 IOP claim, and billers need to see which is which at the line level. The denial queue is organized per line, per claim, per practice, with notes, status tracking, and appeal workflow surfaces.

For ERA review, Medi imports 835 remittance files and presents payment at the line level, with the billed amount alongside the paid amount and any adjustment reason codes. For per-diem residential claims where a payer adjusts some days and pays others, each day's adjudication is reviewable rather than collapsed into a claim-level total.

For work queues, Medi supports practice-scoped and provider-scoped permissions, so a billing company with multiple SUD facilities can assign billers to specific facilities without exposing the rest of the book, while supervisors see across all of it.

For UDT documentation patterns, Medi does not audit clinical documentation. It surfaces denial reason codes when payers flag frequency or medical necessity, and it gives billers a structured surface for tracking those denials and the appeals process. The pattern identification and clinical documentation review stay with the compliance function at each facility.

What Medi does not do: it does not generate ICD-10 or CPT codes, does not determine ASAM level of care, does not submit concurrent review documentation, does not negotiate SCAs, and does not produce clinical documentation. Those decisions stay with your billers and clinical staff.

For the broader behavioral health billing context, see behavioral health billing companies. For denial workflow detail, see denial management workflow guide. To see the system, request a demo.

When Medi is not the right fit

Medi is not the right choice if the billing company needs the RCM software to generate or audit clinical documentation for ASAM placement justification or concurrent review submissions. Those belong to a clinical documentation platform or a utilization review service, not a billing operating layer.

If the company's SUD clients run on a single EHR with a fully integrated billing module and a single payer mix, and that setup is working, adding a second billing layer may not justify the overhead. Medi adds the most value when a billing company manages multiple facilities across payers, and when the pain is coordination and queue visibility rather than pure clearinghouse throughput.

If the primary workflow problem is the authorization submission and concurrent review process itself, Medi tracks those statuses but does not automate the submission. A dedicated prior-authorization management platform handles that layer, and some billing companies layer both.

If a company's SUD clients are predominantly Medicaid fee-for-service in states that require direct portal submission outside commercial clearinghouses, confirm whether Medi's Stedi clearinghouse path covers those payers before making a decision.

Frequently asked questions

What is the difference between H0015, H0017, H0018, and H0019?

H0015 covers intensive outpatient program services, typically billed per hour; some state Medicaid programs define it per-session or per-diem. H0017 is the general behavioral health residential per-diem code, covering clinical programming without room and board. H0018 covers short-term residential treatment under 30 days. H0019 covers long-term residential treatment of 30 days or more. When a patient crosses the 30-day residential threshold, the billing code should transition from H0018 to H0019 with documentation supporting the extended stay. Room and board are not included in any of these codes.

How does concurrent utilization review work in SUD billing?

Concurrent review is a continued-stay authorization process where the payer's clinical reviewers evaluate, typically every few days, whether the patient still meets medical necessity criteria for the current level of care. Reviewers may authorize continued stay, require a step-down, or deny additional days. Denied days are not payable unless successfully appealed. For billing companies, the key is knowing each payer's review schedule per facility and ensuring the clinical team submits documentation before each review deadline, not after the denial arrives.

What makes urine drug testing billing high-risk in addiction treatment?

The OIG and commercial payers have both identified UDT billing patterns where every patient receives the highest-panel definitive test at every visit as a standing-order practice rather than an individualized clinical decision. Medicare limits reimbursement to one presumptive and one definitive test per date of service. Specimen validity testing is generally not separately billable. The risk profile is highest for facilities where testing frequency is high relative to level of care and where documentation does not link each test to a specific clinical rationale.

Does MHPAEA apply to SUD treatment claims?

Yes. MHPAEA requires that commercial health plans not impose more restrictive financial or treatment limitations on SUD benefits than on comparable medical benefits. In practice this means prior authorization requirements, concurrent review frequency, and out-of-network reimbursement cannot be systematically worse for SUD than for medical admissions. The 2024 final rules, effective for most plans in 2025 and 2026, require plans to conduct and produce comparative analyses on these restrictions on request. For billing companies, parity is most relevant in concurrent review appeals and in SCA negotiation when a facility is out-of-network due to an inadequate in-network panel.

What is a single-case agreement and how does it affect billing?

A single-case agreement is a temporary, patient-specific contract between an out-of-network SUD facility and a commercial insurer for one episode of care. It establishes a negotiated per-diem rate, the authorized level of care, the initial authorized stay length, and the concurrent review schedule. Claims billed under an SCA must reference the SCA authorization number and follow the billing codes and rate agreed in the SCA. Concurrent review under an SCA can be more frequent than standard in-network timelines. SCA billing still uses standard HCPCS and CPT codes, and denials still generate CARC and RARC codes on the 835 remittance.

How is MAT billing different at an OTP versus an office-based practice?

Medicare-enrolled opioid treatment programs bill MAT services using weekly G-code bundles: G2067 for methadone, G2068 through G2072 for buprenorphine by formulation, G2073 for naltrexone. These bundles include counseling, group therapy, and toxicology when performed, and a single unit covers seven days. Office-based opioid treatment practices that prescribe buprenorphine but are not certified OTPs do not use G-code bundles; the visit is billed with standard E/M codes and the medication is filled at a pharmacy. Medicaid MAT billing varies by state.